| Literature DB >> 35685622 |
Hamideh P Fallah1, Ekta Ahuja1, Haoquan Lin1, Jinlong Qi2, Qian He3, Shan Gao3, Hailong An3, Jian Zhang3, Yongzhen Xie3, Dong Liang1,3,4.
Abstract
Transient receptor potential (TRP) proteins are a large group of ion channels that control many physiological functions in our body. These channels are considered potential therapeutic drug targets for various diseases such as neurological disorders, cancers, cardiovascular disease, and many more. The Nobel Prize in Physiology/Medicine in the year 2021 was awarded to two scientists for the discovery of TRP and PIEZO ion channels. Improving our knowledge of technologies for their study is essential. In the present study, we reviewed the role of TRP channel types in the control of normal physiological functions as well as disease conditions. Also, we discussed the current and novel technologies that can be used to study these channels successfully. As such, Flux assays for detecting ionic flux through ion channels are among the core and widely used tools for screening drug compounds. Technologies based on these assays are available in fully automated high throughput set-ups and help detect changes in radiolabeled or non-radiolabeled ionic flux. Aurora's Ion Channel Reader (ICR), which works based on label-free technology of flux assay, offers sensitive, accurate, and reproducible measurements to perform drug ranking matching with patch-clamp (gold standard) data. The non-radiolabeled trace-based flux assay coupled with the ICR detects changes in various ion types, including potassium, calcium, sodium, and chloride channels, by using appropriate tracer ions. This technology is now considered one of the very successful approaches for analyzing ion channel activity in modern drug discovery. It could be a successful approach for studying various ion channels and transporters, including the different members of the TRP family of ion channels.Entities:
Keywords: drug discovery; flux assay; ion channel reader (ICR); non-radiolabeled ionic flux; transient receptor potential (TRP) channels
Year: 2022 PMID: 35685622 PMCID: PMC9170958 DOI: 10.3389/fphar.2022.914499
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
Transient receptor potential channels (TRP ion channels) groups and subfamilies.
| TRP ion channels superfamily | |||||||
|---|---|---|---|---|---|---|---|
| Group 1 | Group 2 | Group TRPY | |||||
| G1 | Subfamilies | G2 | Subfamilies | GTRPY | Subfamilies | ||
| S-1 | TRPC | TRPN | S2-1 | TRPML | TRPP | S-1 | TRPY |
| S-2 | TRPS | TRPM | |||||
| S-3 | TRP VL | TRPV | |||||
| S-4 | TRPA | — | |||||
Compounds under clinical trials to target the transient receptor potential channels (TRP ion channels). The information was retrieved from the ClinicalTrials.gov database.
| Channel | Compound | Condition | MOA | Primary outcome | Status | Clinical trial Number |
|---|---|---|---|---|---|---|
| TRPV1 | SB-705498 | Migraine | Antagonist | Pain-free at 2 h post-dose | Phase II completed | NCT00269022 |
| SB-705498 | Dental pain | Antagonist | Reduction in pain intensity using Visual Analogue Scale | Phase II completed | NCT00281684 | |
| SB-705498 | Rhinitis | Antagonist | Mean total symptom score elicited by 1-h cold air challenge | Phase II completed | NCT01424514 | |
| NEO6860 | Osteoarthritis | Antagonist | Safety and tolerability of NEO6860 | Phase I completed | NCT02337543 | |
| PAC-14028 cream 1.0% | Atopic Dermatitis | Antagonist | Percent of patients with IGA score of 0 (clear) or 1 (almost clear) | Phase III completed | NCT02965118 | |
| XEN-D0501 | Chronic Idiopathic Cough | Antagonist | Reduction in daytime cough frequency | Phase II completed | NCT02233699 | |
| TRPV2 | Probenecid | Fontan | Agonist | Improvement in End Diastolic and End Systolic Volume | Phase IV completed | NCT03965351 |
| TRPV6 | SOR-C13 | Cancer | Antagonist | Toxicity | Phase I completed | NCT01578564 |
| TRPM8 | Methoxypropanediol | Non Randomized parallel | Atopic Dermatitis | Antagonist | Mitigation of pruritus markers | NA |
| TRPC5 | GFB-887 | Randomized parallel | Diabetic nephropathy | Antagonist | Percentage change in Urine Protein-to-Creatinine Ratio (UPCR) | Phase II recruiting |
A list of studies reporting the TRP ion channel drug discovery using techniques other than Ion Channel Reader (ICR) technology.
| TRP Ion Channel | Technique used | Model | Drug, agonist antagonist | Reference |
|---|---|---|---|---|
| TRPM2 | Ca2+-sensitive fluorescence dye, Fluo-4 NW | Novel suspension B lymphocyte cell line | TRP channel modulator |
|
| TRPC4 | Whole-cell patch-clamp | HEK293 cells | ML204, antagonist |
|
| TRPM8 | QPatch HT | Menthol activated ion channel | Antagonist |
|
| TRPM7 | Mn2+ sensitive fluorescent dye | HEK293 cells | Antagonist |
|
| TRPV1 and TRPM8 | Ca2+-sensitive fluorescence dye, Fluo-4 NW | Puro MEM culture media | Antagonist |
|
| TRPM8 | Radiometric Calcium imaging and electrophysiology using FLIPR | cold, voltage, and phosphatidylinositol-4,5-bisphosphate activated ion channel | Agonist |
|
| TRPV1 | Automated patch clamp | TRPV1-null mice | Antagonist |
|